Skip to main content
. Author manuscript; available in PMC: 2014 May 29.
Published in final edited form as: Science. 2013 Dec 5;343(6167):152–157. doi: 10.1126/science.1246886

Fig. 2. Vβ-family usage and CDR3 length in patient SCL-42 PBMCs stimulated with WT or mutant peptides.

Fig. 2

SCL-42 PBMCs were stimulated for 6 days with patient-specific mutant (gray bars) and corresponding WT (black bars) RPC1 peptides. No appreciable differences in TCR diversity were observed in Vβ8 (A), Vβ17 (B), and Vβ20 (C) TCR families. Skewing of the CDR3 length distribution in Vβ7 (D), Vβ12 (E), and Vβ24 (F) TCR families was observed, and CDR3 lengths that differed by >15% between WT and mutant stimulated PBMCs are indicated (*). CDR3 length is expressed in amino acids (a.a).